Clomid Vs Enclomiphene For Low Testosterone In Men

Clomid (clomiphene citrate) and enclomiphene are selective estrogen receptor modulators (SERMs) prescribed off-label for men with low testosterone. Both drugs block estrogen receptors in the hypothalamus to stimulate the body's own testosterone production, but they aren't the same medication. Clomid contains two isomers: enclomiphene (the anti-estrogenic isomer) and zuclomiphene (an estrogenic component with a longer half-life). Enclomiphene is the purified version, isolated from that estrogenic counterpart. A 2024 retrospective study of 66 men found that enclomiphene produced 82% fewer adverse events than clomid, with the difference driven largely by zuclomiphene's estrogenic activity (Saffati et al., 2024). Neither medication holds FDA approval for treating male hypogonadism.

What Are Clomid and Enclomiphene?

Clomid has been used in medicine since the 1960s, originally FDA-approved for ovulation induction in women. It's a racemic mixture, meaning it contains two mirror-image molecules that behave differently in the body. Enclomiphene (the trans-isomer) acts as an estrogen antagonist. It blocks estrogen signaling in the hypothalamus, which triggers the pituitary gland to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Those hormones then signal the testes to produce testosterone.

Zuclomiphene (the cis-isomer) does the opposite. It acts as an estrogen agonist, mimicking estrogen in certain tissues. It also carries a longer half-life, so it accumulates with repeated dosing. This buildup is thought to contribute to many of the estrogenic side effects men report on clomid: breast tissue tenderness, mood disturbances, and rising estradiol levels.

Enclomiphene as a standalone compound was developed under the brand name Androxal, but the FDA never approved it for any indication. It's available through compounding pharmacies under 503A and 503B regulations when prescribed by a licensed clinician. Because compounded medications don't undergo the same manufacturing oversight as FDA-approved drugs, patients should confirm their pharmacy follows current USP compounding standards.

How SERMs Stimulate Testosterone Production

Both medications work through the hypothalamic-pituitary-gonadal (HPG) axis. By blocking estrogen receptors in the hypothalamus, they partially block the negative feedback loop that normally limits gonadotropin release. The pituitary responds by increasing LH and FSH output, and the testes respond by producing more testosterone.

This mechanism differs from testosterone replacement therapy (TRT) in one critical way. TRT introduces exogenous testosterone, which suppresses LH and FSH through negative feedback, reduces intratesticular testosterone, and can impair sperm production. SERMs do the opposite: they raise LH, FSH, and testosterone at the same time.

The American Urological Association (AUA) guidelines mention clomiphene as an off-label option for men with testosterone deficiency, especially those who want to preserve fertility (Mulhall et al., 2018). Enclomiphene doesn't appear in current guidelines as a separate recommendation because it lacks FDA approval, but some clinicians prescribe it based on emerging data.

Clinical Evidence on Efficacy and Estradiol

The most direct comparison comes from a 2024 retrospective study at Baylor College of Medicine. Saffati et al. followed 66 hypogonadal men who were first prescribed clomid, then switched to enclomiphene (Saffati et al., 2024):

• Median testosterone increase: 166 ng/dL with enclomiphene vs. 98 ng/dL with clomid (P=0.20)

• Median estradiol change: -5.92 pg/mL with enclomiphene vs. +17.50 pg/mL with clomid (P=0.001)

• Overall adverse events: 13.8% with enclomiphene vs. 47% with clomid (P=0.001)

The testosterone difference didn't reach statistical significance, but the estradiol difference did. That gap matters. A New England Journal of Medicine study found that sexual desire scores dropped 13% in men with testosterone between 200-400 ng/dL when estradiol levels were at or above 10 pg/mL, and by 31% when estradiol fell below 10 pg/mL (Finkelstein et al., 2013). Estradiol balance plays a role in libido, mood, and body composition, and enclomiphene appears less likely to disrupt it.

A 2025 systematic review and meta-analysis of 10 randomized controlled trials (819 patients) also confirmed that SERMs increased total testosterone by a mean of 273.76 ng/dL compared to placebo (95% CI: 191.87-355.66, P<0.01), with results comparable to testosterone gel (Hohl et al., 2025).

How Do Side Effects Compare?

The Saffati et al. (2024) data provides the clearest breakdown.

Regression analysis confirmed men on enclomiphene had 82% lower odds of any adverse event (OR: 0.18, 95% CI: 0.07-0.44, P=0.02). The pattern is consistent. Most of clomid's side effects are thought to relate to zuclomiphene's estrogenic activity. Removing that isomer appears to improve tolerability, though larger controlled trials are needed to confirm.

Visual disturbances, including blurred vision, are a recognized class effect of SERMs and should be discussed with patients before starting therapy.

One limitation worth noting is that this study had no washout period between medications. Because zuclomiphene has a long half-life, residual levels may have influenced early enclomiphene results. Larger randomized controlled trials are still needed.

Can SERMs Preserve Male Fertility?

Fertility preservation is the primary clinical reason providers prescribe SERMs instead of TRT. Exogenous testosterone suppresses the HPG axis, which can reduce sperm counts to near-zero levels in some men. That suppression can take months to reverse, and full recovery isn't guaranteed.

SERMs work differently. By raising LH and FSH, they stimulate both testosterone production and spermatogenesis. A 2023 retrospective study found that men treated with enclomiphene showed improvements in sperm motility and total motile sperm count (TMSC). Before treatment, 75% of men in the enclomiphene group had a TMSC below 5 million. After treatment, that dropped to 50% (Thomas et al., 2023).

For men who want to keep fertility options open, SERMs offer a mechanistic advantage over TRT alone by supporting both testosterone production and spermatogenesis.

Monitoring and Safety Requirements

Any man taking a SERM for low testosterone needs regular lab monitoring. The Endocrine Society recommends diagnosing hypogonadism only when symptoms are present alongside consistently low testosterone, confirmed by two separate early-morning blood draws (Bhasin et al., 2018).

Monitoring on SERM therapy should include total and free testosterone, estradiol (especially on clomid, where levels tend to rise), LH and FSH to verify HPG axis response, hematocrit to screen for erythrocytosis, and liver function since both medications are processed hepatically.

Follow-up bloodwork is typically drawn 6-12 weeks after starting treatment, then every 6 months. Men preparing for their first labs should follow proper blood draw preparation protocols to avoid skewed results.

Choosing Between Clomid and Enclomiphene

The current evidence favors enclomiphene for tolerability. Fewer side effects, more stable estradiol levels, and comparable testosterone increases may make it a reasonable first-choice SERM for many men, though treatment decisions should be individualized. The Saffati study, while small, showed statistically meaningful differences in libido, energy, and mood.

Clomid still has a role. It's more available, less expensive, and has decades of clinical use behind it. For men who tolerate it well, switching isn't always necessary.

Neither medication is a first-line treatment in current guidelines, and neither replaces a proper diagnostic workup. Two morning testosterone lab tests, clinical evaluation by a licensed provider, and an honest conversation about fertility goals should come before any prescription. Because both medications are prescribed off-label for this indication, informed consent should include a discussion of the limited regulatory review for this use. Men weighing clomid vs enclomiphene for low testosterone benefit most from working with a provider experienced in hormone therapy who can match the approach to their lab results and clinical history.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

How do clomid and enclomiphene affect estradiol differently? 

Clomid tends to raise estradiol because it contains zuclomiphene, an isomer with estrogenic activity and a long half-life. In the Saffati et al. (2024) study, men on clomid saw a median estradiol increase of 17.50 pg/mL, while men on enclomiphene saw a median decrease of 5.92 pg/mL (P=0.001). That difference may help explain why enclomiphene tends to produce fewer estrogenic side effects.

Is enclomiphene FDA-approved for low testosterone in men? 

No. Enclomiphene has never received FDA approval for any indication. It was developed under the brand name Androxal for male hypogonadism, but the application did not gain approval. Clomid is FDA-approved only for ovulation induction in women. Both medications are used off-label when prescribed for men with low testosterone.

Can men take clomid or enclomiphene and still maintain fertility? 

Yes. Unlike TRT, which suppresses LH and FSH and can reduce sperm production to near-zero levels, SERMs raise LH and FSH while increasing testosterone. A 2023 study found that 75% of men on enclomiphene with a total motile sperm count below 5 million improved to 50% after treatment. This makes SERMs an option worth discussing for men planning to have children.

What are the most common side effects of clomid in men? 

The Saffati et al. (2024) study found that 47% of men on clomid reported adverse events. The most common were decreased libido (33.3%), erectile dysfunction (18.2%), fatigue (18.2%), decreased energy (16.7%), and mood changes (9.1%). These side effects are thought to relate to zuclomiphene's estrogenic activity.

How long does it take for a SERM to raise testosterone levels? 

Most clinicians check follow-up bloodwork 6-12 weeks after starting therapy. Clinical experience suggests noticeable improvements in energy and libido often begin within 4-8 weeks, though lab confirmation is required to verify the medication is working and to adjust dosing if needed.

What labs should be checked before starting a SERM? 

At minimum, providers should order total testosterone (drawn on two separate mornings between 8-10 AM), free testosterone, estradiol, LH, FSH, hematocrit, and liver function tests. The Endocrine Society defines hypogonadism as consistently low testosterone plus clinical symptoms. Lab values alone don't qualify for diagnosis.

Can clomid or enclomiphene be used alongside TRT? 

Some clinicians prescribe SERMs alongside TRT to maintain LH/FSH levels and support spermatogenesis. This combination approach isn't covered in major guidelines but is used in clinical practice for men who need both testosterone support and fertility preservation. Any combination protocol requires close lab monitoring.

References

• Transl Androl Urol. 2024;13(9):1984-1990

• Cureus. 2023;15(7):e41476

• Arch Endocrinol Metab. 2025;69(5)

• J Urol. 2018;200(2):423-432

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• N Engl J Med. 2013;369(11):1011-1022